Startups

Axoft

Cambridge, Massachusetts, United States

Axoft Inc., clinical-stage developer of ultrasoft implantable neural interfaces and Fleuron materials. CEO/co-founder Paul Le Floch. Disclosed seed $8M and April 2026 Series A $55M total $63M across those rounds; unrelated to similarly named software companies.

Founded 2021

Team

Jia LiuScientific advisor and co-founder

Matt DeNardoChief Product Officer

Oliver ArmitageChief Clinical and Data Officer

Paul Le FlochCEO and co-founder

Tianyang YeCTO and co-founder

Investments

$55M2026-04-29	C.P. Group Innovation, Alumni Ventures, Stanford President's Venture Fund, Hillhouse Investment, Gaorong Ventures
$8M2022-10-18	The Engine, Ab Initio Capital, Decent Capital, Alumni Ventures, Safar Partners, AIBasis, LiquidMetal VC, Taihill Venture, Amino Capital, Blindspot Ventures, Mintz

team@apexlogos.ai4 hours ago
RELATED
team@apexlogos.ai4 hours ago
BCI research snapshot, reviewed 2026-10-06. Company identity: Axoft. This is the pre-import evidence dossier; historical statements about database absence or review are archival. Unverified claims remain research leads, not validated facts. Part 1/1 # Axoft Reviewed 2026-10-06. Research only; no database writes. Proposed ID: `Axoft`. ## Identity and import decision **Validated company; propose a new company after review.** Legal name Axoft Inc.; official site [axoft.us](https://axoft.us/). Founded 2021; Cambridge, Massachusetts, US; private clinical-stage company developing ultrasoft implantable neural interfaces. The current website names the five executives below. [About](https://axoft.us/about), [2022 company launch](https://www.businesswire.com/news/home/20221018005192/en/Axoft-Launches-Brain-Implant-Technology-to-Treat-Long-Term-Neurological-Disorders-and-is-Granted-FDA-Breakthrough-Device-Designation). Read-only `Org` search of `data/db.sqlite3` found no Axoft name match. Avoid Axoft Argentina (`axoft.com`) and the software distributor (`axoftglobal.com`): these are different entities. ## Audit of the pasted entry | Pasted claim | Finding | |---|---| | Axoft; active | Valid company with active research and company announcements. | | $55M total funding | **Incorrect framing.** $55M is the April 2026 Series A. Company says more than $60M cumulatively. The two disclosed rounds below sum to $63M; this arithmetic is a documented-round subtotal, not an independently audited lifetime total. | | axoft-fleuron | Fleuron is the proprietary polymer/material platform used in the implantable BCI, also commercialized through Axoft Materials. Treat the material and implant as distinct products. | | HQ/CEO omitted | Cambridge; Paul Le Floch, CEO and co-founder. | [2026 company financing release](https://www.businesswire.com/news/home/20260429285106/en/Axoft-Secures-%2455M-Series-A-to-Advance-Clinical-Trials-Globally-for-its-Bio-Inspired-Implantable-Brain-Computer-Interface), [company news index](https://axoft.us/news). ## Images and public team Company profile image (official `og:image`, promotional artwork rather than a square logo): [direct image](https://optimise2.assets-servd.host/axoft-website/production/uncropped/SEO_v1.jpg?w=1200&h=630&q=82&auto=format&fit=crop&dm=1666356616&s=0d917717f2df1ed2c1e5db55d1d2af89). Source: [About HTML](https://axoft.us/about). Images below were extracted from each person's `data-srcset`; preserve complete query strings. | Person | Role and status | Profile / evidence | Direct profile-picture URL | |---|---|---|---| | Paul Le Floch | CEO and co-founder; current | [Official profile](https://axoft.us/about) | [Paul Le Floch photo](https://optimise2.assets-servd.host/axoft-website/production/headshots/Paul_2022-10-17-163320_rbfl.jpg?w=456&h=707&q=90&fm=webp&fit=crop&dm=1666024401&s=d277f605e9c7d0728ed965ee02262b2d) | | Tianyang Ye | CTO and co-founder; current | [Official profile](https://axoft.us/about) | [Tianyang Ye photo](https://optimise2.assets-servd.host/axoft-website/production/headshots/Tianyang_2022-10-17-163338_ioty.jpg?w=456&h=707&q=90&fm=webp&fit=crop&dm=1666024418&s=679a5a6da667604f9872ff5e0a591d19) | | Jia Liu | Scientific advisor and co-founder; current | [Official profile](https://axoft.us/about) | [Jia Liu photo](https://optimise2.assets-servd.host/axoft-website/production/headshots/Jia.jpg?w=456&h=707&q=90&fm=webp&fit=crop&dm=1666040015&s=5bf1e0144c8dbc29c465ec8788459e7f) | | Matt DeNardo | Chief Product Officer; current | [Official profile](https://axoft.us/about) | [Matt DeNardo photo](https://optimise2.assets-servd.host/axoft-website/production/headshots/Matt-DeNardo_LR.jpg?w=768&h=1248&q=60&fm=webp&fit=crop&dm=1678195077&s=835d36b3444ad9077e9806b45c839612) | | Oliver Armitage | Chief Clinical and Data Officer; current | [Official profile](https://axoft.us/about) | [Oliver Armitage photo](https://optimise2.assets-servd.host/axoft-website/production/headshots/oliver_2025-04-21-181239_cchn.jpg?w=1200&h=1950&q=82&fm=webp&fit=crop&dm=1745259159&s=9537191a180322848e6e8a0375eaf59c) | ## Investments | Announced | Amount | Type | Lead | Other named participants | Evidence | |---|---:|---|---|---|---| | 2022-10-18 | USD 8M | Seed equity | The Engine | Ab Initio Capital; Decent Capital; Alumni Ventures; Safar Partners; AIBasis; LiquidMetal VC; Taihill Venture; AMINO Capital; Blindspot Ventures; Mintz | [Company announcement](https://www.businesswire.com/news/home/20221018005192/en/Axoft-Launches-Brain-Implant-Technology-to-Treat-Long-Term-Neurological-Disorders-and-is-Granted-FDA-Breakthrough-Device-Designation) | | 2026-04-29 | USD 55M | Series A equity | C.P. Group Innovation | Alumni Ventures; Stanford President's Venture Fund; Hillhouse Investment; Gaorong Ventures; existing investors not individually named | [Company announcement](https://www.businesswire.com/news/home/20260429285106/en/Axoft-Secures-%2455M-Series-A-to-Advance-Clinical-Trials-Globally-for-its-Bio-Inspired-Implantable-Brain-Computer-Interface) | Grant funding from the Massachusetts Manufacturing Innovation Initiative is described in the 2026 financing announcement; amount not disclosed in that release. Keep grants separate from equity. No verified debt round or acquisition identified. ## Review caveats FDA Breakthrough designation in 2022 is not marketing clearance. Clinical and material performance statements in company releases remain company claims. No valuation was disclosed in either round. Do not use third-party Axoft profiles that attach this financing to an ERP business in Argentina.